Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

NCT07158164 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT07158164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07158164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 4
Overall status
Recruiting
Start date
August 27, 2025
Completion date
July 7, 2029
Enrollment
100 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, colorectal neoplasms, gastro-intestinal intraepithelial neoplasia, head and neck neoplasms